Tessa Therapeutics’ Autologous and Allogeneic Cell Therapy Data to be Featured at the 17th International Conference on Malignant Lymphoma, Lugano
30 mai 2023 06h12 HE
|
Tessa Therapeutics Ltd
SINGAPORE, May 30, 2023 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and...
Skin Graft Market (Product, Graft Thickness) - Reach $1.67Bn by 2028 at 7% CAGR with Autologous Segment Driving Growth During 2021–2028 | The Insight Partners
18 mai 2023 10h54 HE
|
The Insight Partners
Pune, India., May 18, 2023 (GLOBE NEWSWIRE) -- The Insight Partners published latest research report on "Skin Graft Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product, Graft...
Cellectis Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T-cells at ASGCT 2023
17 mai 2023 16h30 HE
|
Cellectis Inc.
NEW YORK, May 17, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on a Novel Treatment Paradigm for Successful CAR T Immunotherapy Against Stroma-rich Solid Tumors
12 mai 2023 01h30 HE
|
Cellectis Inc.
NEW YORK, May 12, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023
11 mai 2023 10h20 HE
|
Cellectis Inc.
NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Monthly information on share capital and company voting rights
10 mai 2023 16h30 HE
|
Cellectis Inc.
NEW YORK, May 10, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of shares in the capitalTotal number of voting...
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2023
04 mai 2023 16h30 HE
|
Cellectis Inc.
First r/r ALL patient dosed in Europe with Cellectis’ UCART22 product candidate manufactured in-houseCellectis implements CLLS52 for the first time in the clinic with Sanofi’s alemtuzumabCellectis...
Cellectis Announces Oral Presentation on AMELI-01 and Poster Presentation on Multiplex Engineering for Superior Generation of CAR T-cells at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
02 mai 2023 16h35 HE
|
Cellectis Inc.
NEW YORK, May 02, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofi’s Alemtuzumab
24 avr. 2023 16h30 HE
|
Cellectis Inc.
Cellectis demonstrated that the addition of alemtuzumab to the lymphodepletion regimen was associated with prolonged lymphodepletion and significantly higher cell expansion and clinical activity NEW...
Cellectis Presents Preclinical Data on TALEN®-edited MUC1 CAR T-cells to Enhance Efficacy in Targeting Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting
17 avr. 2023 02h00 HE
|
Cellectis Inc.
NEW YORK, April 17, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...